INTRODUCTION
Lentigo Maligna and LM Melanoma (LM/LMM) are subtypes of melanoma occurring on chronically sundamaged skin, mainly on the head and neck, and its annual incidence is increasing [1, 2] . LM can be diagnostically challenging, even for experienced dermatologists, due to overlapping features with benign pigmented lesions, such as macular seborrheic keratosis, pigmented actinic keratosis, and solar lentigines [3] . Benign solar lentigines are present in an estimated 90% of lighter Fitzpatrick phototype individuals over age 60, and are a common cosmetic concern prompting elective treatment [4] . Misdiagnosis can have important consequences, as procedures used to treat benign pigmented lesions may be inadvertently performed on LM. As such, there have been reported cases of patients referred for cosmetic removal of benign pigmented lesions that were found to be LM on histological evaluation [5] .
There is an aging population with a growing interest in cosmetic procedures and focus on decreasing the signs of aging, complicated by increasing rates of skin cancer. Cosmetic treatments including cryotherapy, laser therapy, or topical bleaching agents are used commonly to treat clinical pigmentation, but may obfuscate the subsequent detection of malignancy due to dyspigmentation or scarring, delaying diagnosis [6] [7] [8] . The actual incidence of LM previously treated cosmetically as benign pigmented lesions is unknown, and difficult to assess due to the indolent natural history of LM development. It is also unknown if cosmetic treatment of lesions that were later identified as LM result in worse clinical outcomes.
OBJECTIVE
The aim of this study is to determine the prevalence of biopsy-proven LM that presented for definitive treatment following a history of cosmetic treatment, and to evaluate if prior cosmetic treatment complicates management and prognosis.
METHODS
Following Institutional Review Board approval, a prospectively collected database of all biopsy-proven LM/ LMM presenting to a dermatologic surgery practice at a cancer center for management between 2006 and 2015 was retrospectively reviewed. Upon initial presentation, patients were asked if they had received prior cosmetic treatment of their biopsy-proven LM/LMM (including cryotherapy, laser treatments, electrodessication and/or curettage, or topical bleaching creams). Patients were also asked if they had a history of prior biopsy from the lesion. Outside pathology reports for prior benign biopsies were obtained. For any LM/LMM with a history of prior cosmetic treatment, records were reviewed for demographic data along with presenting clinical characteristics and surgical outcomes. All patients underwent surgical excision with a staged technique and rush paraffin-embedded permanent sectioning with serial sections for extent of residual LM and presence or absence of invasive tumor as previously described [9] . Pathology reports were reviewed, including final depth of invasion. Cases that were previously treated solely with surgical excision or with topical imiquimod were excluded.
RESULTS

Clinical Characteristics
Five hundred three patients meeting inclusion criteria were treated for biopsy-proven LM/LMM from 2006 to 2015. Of these, 37 patients (7.4%) reported a history of prior cosmetic treatment of their lesion ( Table 1 ). The average age of patients with prior cosmetic treatment was 61 (range: 34-81), with 17 men (46%) and 20 women (54%). All patients had Fitzpatrick phototype I-III. Of the most common locations, seventeen lesions presented on the cheek (45.9%), followed by eight on the forehead (21.6%) and five on the nose (13.5%). Overall, 35/37 (95%) were located on the head, with the other two on the extremities. The mean size of the lesion on presentation was 1.9 cm, ranging from 0.3 to 5.5 cm in longest clinical diameter.
Cosmetic Treatments
Prior cosmetic treatment included cryotherapy, laser, topical bleaching agents, and electrodessication and/or curettage. The majority of patients reported prior treatment with cryotherapy (73%, n ¼ 27) either alone or in combination with other treatments, followed by laser treatment (29.7%, n ¼ 11), topical bleaching agents (18.9%, n ¼ 7), and electrodessication and/or curettage (5.3%, n ¼ 3). Ten patients (27%) were treated with two or more treatment modalities (Table 1 ).
Previous Biopsy Characteristics
Eight patients (8/37; 21.6%) reported a history of benign biopsy, with three patients having multiple prior benign biopsies ( Table 1 ). The biopsies were performed between 1 month and 8 years prior to LM diagnosis. Benign biopsy diagnoses included seborrheic keratosis, nevus, solar lentigo, and lichen planus-like keratosis.
Histopathologic Characteristics:
Overall, six patients (6/37; 16.2%) had invasive disease either on biopsy or excision. Two cases were diagnosed as LMM on initial biopsy, and four of the remaining 34 cases treated surgically (11.7%) were initially diagnosed as LM on biopsy but revealed an invasive component upon complete excision. Depths of invasive disease ranged from 0.2 mm to 1.25 mm (Table 1) .
Surgical Outcomes
All patients except one were treated with staged surgical excision for complete margin control. One patient was treated at an outside institution. The average margin needed to clear the lesion was 9.1 mm (range 3-23 mm). Fifteen of 36 patients (42%) treated with staged surgical excision required at least 10 mm margins. The mean number of stages to clear the lesion was 2.1 (range 1-5).
The average clinical lesion size in longest diameter for the six invasive lesions was 2.98 cm (0.9-5.5 cm). The average margins were 11.33 mm, with 2.2 stages to clear the lesion. For the lesion with depth 1.25 mm (focal Clark IV involvement), lymphoscintigraphy was attempted but a dominant nodal basin was not identified. Considering the subset of non-invasive lesions, the average clinical lesion size was 1.71 cm (0.3-4.5 cm). The average margin for noninvasive lesions was 8.63 mm, with 2.0 stages required for clearance.
DISCUSSION
There is an aging population with growing interest in cosmetic procedures to reverse the signs of aging. In this study the prevalence of LM/LMM reported to have been previously treated cosmetically as a benign pigmented lesion was 7.4%. As the incidence of LM/LMM continues to increase, providers must be aware of lesions not responding to conventional treatments, and be cautious of presumed benign pigmented lesions that deviate morphologically prior to treating cosmetically. The average age in our series (61) is lower than the reported 65-70 years [9] [10] [11] [12] , reflecting both the increased interest in cosmetic procedures among younger individuals and that the incidence of melanoma in situ is increasing, with a faster rate in younger populations [13] . Interestingly, nearly 50% of the patients in our series were male, which reflect current trends that more men are seeking cosmetic procedures [14] . Notably, over a quarter of patients were treated with multiple modalities, suggesting multiple clinic visits or time points to reassess the lesion. Although the setting and qualifications of providers performing cosmetic treatments in this study is not known, the findings reinforce that skin lesions should be evaluated by individuals appropriately trained in evaluating skin and cosmetic concerns. LM is an indolent form of melanoma that evolves slowly and is often present for years prior to diagnosis. These lesions have a slow rate of invasion, and controversy exists regarding management and optimal surgical margins. Early detection and adequate treatment with negative margins is important prior to progression to invasive melanoma. It has been well-established in the dermatology literature that standard 5 mm margins are inadequate for complete margin control in large series of LM [11, [15] [16] [17] [18] . In a previously published series from our institution utilizing the same staged surgical technique, the margins required for clearance of LM was 7.1 mm, and for LMM was 10.3 mm [9] . In the current study, the margins required for clearance of cosmetically treated LM were even wider (8.6 mm for LM, 11.3 mm for LMM). Moreover, 15/36 patients in this series (42%) required at least 10 mm margins. This suggests the clinical borders may have been obscured by prior therapies aimed at destroying surface pigment, or there may have been a delay in diagnosis while treating as a benign pigmented lesion allowing for further radial growth (Fig. 1) . In the author's experience, skip areas have been occasionally observed but the true incidence is unknown. Overall, the rate of upstaging from LM to invasive disease upon final excision (11.7%) was high but within the expected range compared with other recently reported rates of upstaging for LM and melanoma in situ (4-11.7%) [15, [19] [20] [21] . Thus, the prior cosmetic treatment did not appear to have an effect on overall prognosis, but the wider surgical margins resulted in larger defects creating reconstructive challenges and increased morbidity. Long-term follow-up is required to determine if these lesions have higher rates of recurrence, as there may have been interruption in contiguous tumor resulting from their prior cosmetic treatment.
A review of the literature shows 13 previously reported cases of pigmented lesions initially treated cosmetically with cryotherapy and/or laser treatment, later diagnosed as LM/LMM [8, [22] [23] [24] [25] [26] (Table 2 ). The ages range from 59 to 72, with seven males and six females. All were located on the head and neck except one on the upper arm. Those with a benign biopsy at some point prior to cosmetic treatment had the following results: pigmented actinic keratosis, melanocytic nevus, nevoid lentigo, and dysplastic nevus. Of the 13 reported cases, 8 were found to have invasive LMM (61.5%) on final excision and one patient had lymph node metastasis. Additional reports document other forms of melanoma, including nodular, amelanotic, and metastatic, occurring after prior laser or cosmetic treatment of presumed benign lesions [24] [25] [26] [27] [28] . Stankiewicz et al. describe three patients who presented for cosmetic removal of pigmented lesions, two referred by physicians, all found to be LM or melanoma in situ before any cosmetic intervention, underscoring the importance of careful evaluation of presumed benign pigmented lesions before treatment [5] . When patients present for cosmetic treatment of a pigmented lesion on sun-damaged skin, they should be questioned regarding changes in size, color, shape, or other features that are now raising cosmetic concern about the lesion. While it is unreasonable to biopsy every pigmented lesion prior to cosmetic treatment, all warrant thorough clinical and dermoscopic evaluation. Yet, diagnostic accuracy as measured by the number needed to biopsy among dermatologists at two academic centers ranges from 15 to 17.4 for melanoma [29, 30] . Recently, reflectance confocal microscopy (RCM) has seen an emerging role for non-invasively evaluating clinically equivocal pigmented facial lesions, including LM [31, 32] (Table 3) . RCM has acquired Coding Procedural Terminology (CPT) codes (96931-96936), providing reimbursement for image acquisition and interpretation. These images may be acquired longitudinally over time, allowing for repeat non-invasive assessment of areas of skin to guide management, and may help provide a story to the dermatopathologist aiding in biopsy interpretation.
For large, clinically suspicious lesions on sun-damaged skin, a biopsy may be warranted. However, limited sampling via a punch biopsy showing solar lentigo or pigmented actinic keratosis does not exclude the diagnosis of LM [33] . In fact, eight patients in this study reported a history of prior benign biopsies. Sampling error may only reveal mild or moderate melanocytic atypia when LM is present in other areas of the lesion, especially when small, partial biopsies are taken in the interest of preserving cosmesis (Fig. 2) . Variations in size, number, and type of biopsy likely account for the varied rates of upstaging seen after LM diagnosis [21, [34] [35] [36] . This is supported by the observation that institutions performing microstaging (removal of all clinically apparent residual lesion suspicious for invasive disease prior to staged excision) achieve lowest rates of deeper residual disease (3.8%) [37] . In the case of particularly large lesions, incisional biopsy or multiple mapping biopsies should be taken of the most deeply pigmented or thickest areas.
Repigmentation After Cosmetic Treatment
Cosmetic treatments for pigmented lesions (lasers, cryotherapy, chemical peels, electrodessication and curettage, and bleaching agents) target surface pigmentation to improve the cosmetic appearance, but ultimately obscure future clinical examination [38] . The prospect of early LMs being successfully treated with these destructive modalities is possible; however, at this time, neither cryosurgery or laser treatment is recommended for LM due to the high rate of recurrence, potential for adnexal invasive disease, and lack of controlled studies [39, 40] . In the current study, 10 patients reported multi-modality treatments suggesting that the lesion did not respond to an initial treatment. Patients reported their cosmetic treatments occurred over months to years, but the exact time to repigmentation is not known. Clinical repigmentation or persistent pigmentation in lesions previously treated with destructive or [25] 68/M -Cheek -Laser Therapy NOS -No -LMM Delker et al. [26] a note 11 melanomas total in this series
M, male; F, female; NOS, not otherwise specific; CO2, Carbon dioxide; Er:YAG, Erbium:yttrium-aluminum-garnet; n/a, not available; LM, lentigo maligna; LMM, lentigo maligna melanoma. ablative modalities should raise suspicion of potential LM, even with a history of prior benign biopsy. In our series, 29/37 (78%) of LM who received cosmetic treatment did not report a prior biopsy. Other studies have also reported a lack of histological diagnosis prior to treatment of lesions that were melanoma. In a series by Delker et al., 9/11 (82%) lesions that were melanoma had no biopsy prior to cosmetic treatment [26] . Four of these were stage IV disease, and one patient died of melanoma. In another series by Zipser et al., 8/12 (67%) patients had no biopsy prior to cosmetic treatment, 2/12 (17%) were misdiagnosed on review, and only 2/12 (17%) had benign biopsies before treatment [24] . In their series, two patients had stage IV disease, and three died of metastatic melanoma. Gottschaller et al. describe a case of metastatic melanoma after a clinically diagnosed "lentigo simplex" was treated with CO2 laser, and review other cases of malignant melanoma after laser therapy [27] . While it has been shown in vitro that [41] [42] [43] , this mechanism has not been observed in humans. The aforementioned studies in conjunction with the current study demonstrate the potential pitfalls in foregoing histological confirmation of a suspected benign pigmented lesion prior to pursuing cosmetic treatment.
Limitations
Limitations of our current study include possible recall bias regarding which lesions were previously treated. Cryotherapy is routinely used for treatment of facial lesions, and while patients may not exactly recall which ones were treated, it is plausible that these lesions were previously frozen. Secondly, we cannot definitively conclude that a new diagnosis of LM in an area previously treated with cosmetic therapies is evidence that a missed diagnosis of LM occurred. A de novo melanoma or a collision tumor may occur. In the cases of a prior benign biopsy, the area chosen for biopsy may not have captured adequate melanocytic atypia or the foci of invasive disease for correct diagnosis. Another limitation is that this was a single center study; however, this allowed for consistency in surgical technique, histopathologic evaluation, and margin determination. Comparison of our series to others was limited by heterogeneity of lesions included in the study, varying surgical technique, absence of reporting rates of invasion or surgical margins, and an unknown number of patients with prior cosmetic treatment included in other series [10] [11] [12] 19, 44] .
CONCLUSION
Prior cosmetic treatment of LM/LMM presenting for definitive surgical treatment is not uncommon. Overall, the incidence of LM previously treated as a benign pigmented lesion (7.4%) along with the cases reviewed here highlight the need for improved technologies to evaluate suspected benign pigmented lesions or possible LM. The rate of invasive disease was 16%, and 42% of all cosmetically treated LM lesions required at least 10 mm margins, suggesting prior cosmetic treatment may have obscured borders. Lesion assessment with dermoscopy, RCM, or other non-invasive imaging prior to any cosmetic treatments may aid in evaluation. Clinicians must maintain an awareness of possible alternate diagnoses of pigmented lesions, especially for those occurring on sundamaged skin of the head and neck or in cases of residual or recurrent pigmentation. Patients should be consented and educated that if lesions do not resolve, they should return to their dermatologist for follow-up. 
